Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 95Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 16Myelodysplastic Syndromes 15Leukemia 13Leukemia, Biphenotypic, Acute 10Recurrence 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 9Lymphoma, B-Cell, Marginal Zone 8Waldenstrom Macroglobulinemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Multiple Myeloma 6Lymphoma, Follicular 6Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Burkitt Lymphoma 5Neoplasm, Residual 4Leukemia, B-Cell 3Chromosome 17 deletion 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Monocytic, Acute 2Hematologic Neoplasms 2

Interventions

Trastuzumab 5Carboplatin 5130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2pembrolizumab 2Tretinoin 2Paclitaxel 2Immunotherapy 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cytarabine 2zanidatamab 1venetoclax 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tislelizumab 1temsirolimus 1talazoparib 1tagraxofusp 1sarilumab 1sargramostim 1pyrotinib 1pexidartinib 1pazopanib 1patritumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Complete Response × venetoclax × Clear all
NCT07007052 2025-11-26

TAGVEN

French Innovative Leukemia Organisation

Phase 2 Not yet recruiting
33 enrolled
Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡